Relation Between Serum 3-Deoxyglucosone and Development of Diabetic Microangiopathy
- 1 June 2003
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (6), 1889-1894
- https://doi.org/10.2337/diacare.26.6.1889
Abstract
OBJECTIVE—3-Deoxyglucosone (3-DG), a highly reactive intermediate of the glycation reaction, has been suggested to contribute to the development of diabetes complications. To verify this hypothesis, we assessed the relation between serum 3-DG concentrations and the severity of diabetic microangiopathy in diabetic patients. RESEARCH DESIGN AND METHODS—We conducted a high-performance liquid chromatography assay to determine the serum 3-DG concentrations of 110 diabetic patients with different degrees of severity of diabetic microangiopathy and 57 age-matched control subjects. RESULTS—The fasting serum 3-DG level in diabetic patients was significantly (P < 0.001) higher than that in control subjects (353 ± 110 vs. 199 ± 53 nmol/l). The 3-DG levels were significantly (P < 0.001) elevated even in the diabetic patients showing normoalbuminuria (n = 62, 322 ± 79 nmol/l) compared with control subjects. The 3-DG levels were further elevated in the patients with microalbuminuria (n = 30, 383 ± 146 nmol/l) and overt proteinuria (n = 18, 410 ± 100 nmol/l) (P = 0.027 and P < 0.001 vs. normoalbuminuria group, respectively). This phenomenon was basically reproduced in a category of retinopathy. Furthermore, the diabetic patients with low nerve conduction velocity showed a tendency to display higher 3-DG levels. CONCLUSIONS—The present results show that the fasting serum 3-DG level is elevated in diabetic patients and that the patients with relatively higher 3-DG levels were prone to suffer from more severe complications, indicating a possible association of 3-DG with diabetic microangiopathy.This publication has 41 references indexed in Scilit:
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.Journal of Clinical Investigation, 1997
- Accumulation of Pyrraline-modified Albumin in Phagocytes due to Reduced Degradation by Lysosomal EnzymesPublished by Elsevier ,1997
- Induction of Apoptotic Cell Death by Methylglyoxal and 3-Deoxyglucosone in Macrophage-Derived Cell LinesBiochemical and Biophysical Research Communications, 1996
- Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.Journal of Clinical Investigation, 1995
- Presence of 3-Deoxyglucosone, a Potent Protein Crosslinking Intermediate of Maillard Reaction, in Diabetic SerumBiochemical and Biophysical Research Communications, 1993
- Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to ratsBiochimica et Biophysica Acta (BBA) - General Subjects, 1990
- Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue RemodelingScience, 1988
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Relation between Complications of Type I Diabetes Mellitus and Collagen-Linked FluorescenceNew England Journal of Medicine, 1986